医学
前列腺癌
比例危险模型
队列
肿瘤科
内科学
生物标志物
骨骼肌
放射性密度
逻辑回归
前列腺
生存分析
癌症
队列研究
磁共振成像
雄激素剥夺疗法
无进展生存期
泌尿科
总体生存率
转移
生化复发
对数秩检验
回顾性队列研究
试验预测值
放射科
放射性配体
淋巴血管侵犯
危险系数
成像生物标志物
单变量分析
前瞻性队列研究
作者
Christian Immanuel,Thomas Büttner,Alois Martin Sprinkart,Sebastian Nowak,Maike Theis,Jim Küppers,Sibgol Fazeli,Leander Fritzsche,Aland Amin,Dilan Salih,Hojjat Ahmadzadehfar,Florian C. Gärtner,Barbara Kreppel,Rupert Conrad,M Ritter,Markus Essler,Philipp Krausewitz,Milka Marinova
标识
DOI:10.1007/s00259-026-08068-x
摘要
PURPOSE: Skeletal muscle radiodensity (SMD) is an emerging imaging-derived marker of muscle quality. Its prognostic relevance in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy has not yet been systematically evaluated. This study aims to investigate the prognostic value of SMD derived from routine pretherapeutic PET/CT imaging in a large real-world mCRPC cohort treated with [¹⁷⁷Lu]Lu-PSMA-617. METHODS: In this single-center study, the largest to date cohort comprising 410 mCRPC patients was analyzed. SMD was quantified automatically from the L3-level CT component of pretherapeutic [⁶⁸Ga]Ga-PSMA-PET/CT using an AI-based segmentation tool. An optimal SMD cut-off (19.26 HU) was determined for survival stratification. Associations with overall survival (OS) were assessed using multivariable Cox regression (univariable and multivariable, adjusted for baseline PSA) and Kaplan-Meier analysis. RESULTS: Lower SMD was associated with reduced OS (HR 1.87, P<.001). Median OS were significantly shorter in the SMD-low group compared to the SMD-high group (7.6 months vs. 12.2 months; P<.001). This prognostic stratification was seen in both, patients with or without PSA50 or PSA90 response, respectively. SMD correlated with age, albumin, and PSA, but not with BMI. CONCLUSION: SMD assessed from routine pretherapeutic PET/CT is a non-invasive prognostic biomarker in patients undergoing PSMA-targeted radioligand therapy. Integration of host-derived imaging biomarkers such as SMD with tumor-specific parameters may improve risk stratification, prehabilitation and support future individualized treatment strategies in advanced prostate cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI